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were done immediately after the TAVI procedure. Trans-femoral TAVI’s were
associated with higher risk (OR 8.6, 95% CI 3.1 – 28.3) of developing permanent
heart block compared to transapical route (OR 2.4, 95% CI, 1.3 – 4.3). Core Valve
use was associated with a higher risk of developing permanent heart block (OR 2.4,
95% CI 1.6 – 3.6) than Edward Sapiens Valve (OR 1.9, 95% CI 1.2 – 2.8)
compared to SAVR.
Conclusions: Patients undergoing minimally invasive TAVI procedure have a four
times higher risk of developing heart block needing pacemaker implantation compared
to patients undergoing SAVR procedure.
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Background: The Edwards SAPIEN 3 (Edwards Lifesciences, Irvine, CA, USA)
transcatheter heart valve ( S3 THV) incorporates a paravalvular sealing system with
an active 3-dimensional coaxial positioning. No comparisons in clinical practice
have been performed with its predecessor, SAPIEN XT (SXT) with regards to
paravalvular aortic regurgitation (PAR), a predictor of future mortality in TAVR
patients.
Methods: All patients implanted with an Edwards XT or S3 THV, from January 2013
to April 2014 in San Rafaelle Scientiﬁc Institute, Milan, Italy, were included in the
current study. PAR was assessed using aortography and transthoracic echocardiog-
raphy after TAVR.
Results: A total of 61 Edwards SAPIEN transfemoral TAVR were performed (14
S3 and 47 SXT). With the exception of higher percentage of baseline moderate/
severe AR in the Sapiens 3 group (20% SXT vs. 64.3% S3, p¼0.002) baseline
demographics did not differ signiﬁcantly between the groups (Table 1). Balloon
aortic valve predilatation was performed more frequently in the SXT group (95.7%
vs. 28.6%, p< 0.001). In both groups similar valve sizes were used (23/26/29mm:
38.3%/48.9%/12.8% S3 vs. 37.7%/35.7%/28.6% SXT, p0.355). Similar was also
the percentage of postdilatation (23.4 % SXT vs. 21.4% S3, p¼0.877). Final
aortography revealed non/trace PAR in 92.9% S3 vs. 17.9% SXT; mild in 7.1%
S3 vs. 67.7% SXT and moderate/severe in 0% S3 and 15.4% SXT (p< 0.001).
Similar results were obtained when comparing ﬁnal echocardiographic assessment
for PAR. There was a trend for a higher device success (as per VARC-2) amongst
S3 patients (100% vs. 83%, p¼0.180).Baseline
Characteristics Total(N¼61)
Edwards
SAPIEN XT
(N¼47)
Edwards
SAPIEN 3
(N¼14)
P-
value
Age (years) 80.27.0 80.477.0 79.367.3 0.607
Female gender 45.90% 51.10% 28.60% 0.138
Diabetes Mellitus 26.20% 27.70% 21.40% 0.642
Previous myocardial
infarction
9.80% 10.60% 7.10% 0.7
Previous PCI 21.30% 21.30% 21.40% 0.99
Previous CABG 21.30% 19.10% 28.60% 0.45
Logistic EuroSCORE
(%)
18.614.9 18.314.9 19.815.4 0.746
STS Score (%) 5.4 (3.6 to
12.0)
6.3 (3.9 to
13.7)
4.4 (3.2 to
10.0)
0.11
Left ventricular
ejection fraction (%)
53.213.3 52.113.7 56.8 0.25
Mean aortic
annulus (mm) CT
23.91.8 23.81.7 24.52.2 0.214
Minimum ilio-
femoral diameter
(mm)
7.01.2 7.21.2 6.61.0 0.156
Aortic valve area
(cm2)
0.701.2 0.650.16 0.790.19 0.016
Aortic mean
gradient (mmHg)
50.314.5 51.215.6 47.610.6 0.426
Aortic regurgitation
 moderate
30.50% 20% 64.30% 0.002
Mitral regurgitation
 moderate
32.20% 33.30% 28.60% 0.739
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regurgitation when compared to its predecessor SXT.
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Background: Procedural technical features of CoreValve implantation have been
shown to affect the short and long-term outcome after Transcatheter Aortic Valve
Implantation (TAVI). The aim of this study was to evaluate the impact of Cor-
eValve implantation depth on the short-term hemodynamic and procedural
characteristics.
Methods: From June 2008 until February 2013, patients who had undergone TAVI
with the CoreValve device, were retrospectively studied. The device implantation
depth was evaluated in ofﬂine analysis by measuring the distance between the lowest
coronary cusp calcium border, as depicted in the post-implantation aortography, and
the lowest edge of the device frame (smaller measured distance indicating higher
implantation depth, see image). The aortic valve regurgitation (AR) was evaluated
after TAVI and classiﬁed as none, mild and moderate. Finally, the necessity of post-
implantation balloon dilatation in order to achieve a better valve expansion was
recorded.
Results: A total of 119 patients (mean age 80.65.3 yrs, 62 males) were ﬁnally
enrolled. The implantation was performed either transfemoraly, or through subcla-
vian route (12 patients). A statistically signiﬁcant difference was found for the
implantation depth between the three post-TAVI aortic regurgitation classiﬁcations
(8.12mm for none AR, 7.95mm for mild and 6.27mm for moderate AR, p¼0.046),
indicating increased AR with higher device implantation. Similarly, patients who
underwent balloon post-dilatation, had statistical signiﬁcant higher implantation
depth compared with those who didn’t (6.393.2mm vs 8.142.5mm, p¼0.012).
The implantation depth remained an independent predicting factor of balloon post-
dilatation necessity in multivariate logistic regression [OR:0.775 (0.64-0.938),
p¼0.009].
Conclusions: The CoreValve device implantation depth is strongly correlated with the
post-implantation observed aortic regurgitation, as well as with the necessity of
balloon post-dilatation. It seems that, concerning hemodynamic short-term outcome,
operators should be even more careful in device implantation depth ensuring the
optimal positioning.
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Background: In-stent pre-cusp ﬂow acceleration and its importance in the accurate
echo assessment of the Sapien valve are well recognized with stent and valve cusps
contributing to overall valve gradients. The echo ﬂow features of the CoreValve have
not been previously reported.
Methods: Pre-stent (P-S) and in-stent pre-cusp (I-SPC) CoreValve velocities were
measured in 17 consecutive CoreValve pts. Valve sizes (mm) were 26(n¼4),
29(n¼6), and 31(n¼7). Pulsed-wave (PW) Doppler velocity time integral (VTI) was
recorded with sample volume placement at 2 levels: immediately apical to the stent
(P-S) and within the stent just apical to the valve cusps (I-SPC). Effective oriﬁce
area (EOA) ¼ (LVOT CSA X LVOT VTI)/AV VTI and Doppler velocity index
(DVI) ¼ LVOT VTI/AV VTI were calculated using both the P-S and I-SPC for
LVOT VTI.lvular disease - Aortic: TAVR B225
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level of the cusps in all pts. EOA and DVI calculated using P-S values was signiﬁ-
cantly lower than when using I-SPC values. See table.Pre-stent (P-
S)
In-stent pre-cusp (I-
SPC) p
Effective oriﬁce area (EOA),
cm2
1.81  0.36 2.30  0.42 <0.0001
Doppler velocity index (DVI) 0.44  0.10 0.55  0.11 <0.0001
Peak velocity, m/sec 0.80  0.16 1.05  0.22 <0.0001
Peak gradient, mmHg 2.7  1.2 4.6  2.0 <0.0001
Mean gradient, mmHg 1.5  0.8 2.4  1.1 <0.0001
VTI , cm 15.2  3.9 19.2  4.2 <0.0001
Stroke volume, ml 63.9  18.5 81.1  22.9 <0.0001Conclusions: There is hemodynamically signiﬁcant ﬂow acceleration within the
CoreValve stent proximal to the cusps. Failure to recognize the importance of pre-
stent PW Doppler sample volume placement may result in inaccurate and inconsistent
assessment of Corevalve EOA and DVI.
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Background: A postprocedural increase of the serum troponin I concentration (TnI)
reﬂects myocardial injury and occurs frequently during transcatheter aortic valve
implantation (TAVI). Periprocedural coronary microembolization is a potential cause
of such injury. We therefore evaluated each step of the transfemoral TAVI procedureB226 JACC Vol 64/11/Suppl B j Sepfor coronary embolization using intracoronary Doppler (ICD) in the left anterior
descending (LAD) artery.
Methods: 15 high-risk patients with severe, symptomatic aortic valve stenosis who
underwent transfemoral TAVI using the balloon-expandable Edwards bioprosthesis
were included. ICD examinations were recorded and evaluated off-line for high-in-
tensity transient signals (HITS). Perioperative concentrations of TnI were serially
measured within the ﬁrst 72 h after TAVI, and a cardiac MRI with late gadolinium-
enhancement (LGE) was performed within 7 days.
Results: HITS were detected in all patients, mostly during the initial crossing of the
native valve and positioning of the prosthesis with subsequent implantation. TnI
peaked at 24 h after TAVI (3.17 ng/ml), and LGE was observed in only one single
case. There was no correlation between amount of HITS and TnI area under the curve
in the ﬁrst 72 h after TAVI.Conclusions: Procedural HITS were detected by ICD in all patients undergoing
transfemoral TAVI. The highest amount of HITS was observed during initial valve
passage and positioning of the prosthesis with subsequent implantation. However, no
association was found between the number of HITS and myocardial injury, as re-
ﬂected by increased serum TnI concentrations or LGE on cardiac MRI.
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Background: The adverse impact of left ventricular dysfunction on survival after
transcatheter aortic valve implantation (TAVI) has been documented. We report our
experience with transapical TAVI in patients with reduced left ventricular function
(LVEF) comparing ﬁrst (balloon-expandable) and second (self-expanding) generation
TAVI devices.
Methods: From 3/2008 through 12/2012, a total of 75 patients presenting with pre-
procedural LVEF45% underwent transapical TAVI, implanting either balloon-
expandable prostheses (Edwards Sapien/Sapien XT) in 48 patients (BE; mean age
78.27.9 years, 71% male) or self-expanding prostheses (JenaValve, n¼12; Symetis
Accurate, n¼9; Medtronic Engager, n¼6) in 27 patients (SE; mean age 79.56.7
years, 63% male), respectively. Calculated logistic EuroSCORE II and STS mortality
scores were 12.67.4% (BE) vs. 10.85.4% (SE) (p¼ns) and 9.26.6% (BE) vs.
9.27.3% (SE) (p¼ns). Clinical and functional data were analysed according to the
Valve Academic Research Consortium (VARC) endpoints.
Results: Cumulative survival rates at 30 days and at one year were 87.5% (BE) vs.
96.3% (SE) (p¼ns) and 52.0% (BE) versus 60.5% (SE) (p¼ns), respectively. VARC
device success and VARC combined 30-day safety endpoints were achieved in 87.5%
(BE) vs. 85.2% (SE) (p¼ns) and 31.3% (BE) vs. 18.5% (SE) (p¼ns), respectively.
Post-procedural aortic regurgitation >grade 1 did not differ between groups (8.4%
(BE) vs. 11.1% (SE), p¼ns). However, aortic regurgitation grade 1 was observed in
50.0% (BE) vs. 37.0% (SE) (p¼0.016). New onset of pacemaker indication was
present in 10.4% (BE) vs. 7.4% (SE) (p¼ns). Mean ICU stay was 2.52.6 days (BE)
vs. 2.01.8 days (SE) (p¼ns), whilst post-procedural hospital stay was 10.03.8 days
(BE) vs. 10.66.6 days (SE) (p¼ns).
Conclusions: Comparable survival rates and VARC endpoints were achieved in pa-
tients with reduced LVEF undergoing transapical TAVI either with balloon-expand-
able or with self-expanding prostheses. Further studies are required to evaluate the
impact of a lower incidence of mild aortic regurgitation following implantation of self-
expanding valve types when compared to balloon-expandable prosthetic valves.tember 13–17, 2014 j TCT Abstracts/Valvular disease - Aortic: TAVR
